Brainstorm Cell Therapeutics Q2 2026 Earnings Report

Brainstorm Cell Therapeutics EPS Results

• Actual EPS: -$0.35
• Consensus EPS: -$0.29
• Beat/Miss: Missed by -$0.06
• One Year Ago EPS: N/A

Brainstorm Cell Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Brainstorm Cell Therapeutics Announcement Details

• Quarter: Q2 2026
• Date: 8/14/2026
• Time: After Market Closes
• Conference Call Date: Monday, August 17, 2026
• Conference Call Time: 4:00PM ET

Brainstorm Cell Therapeutics (NASDAQ:BCLI) is a biotechnology company developing cell-based therapies for neurodegenerative diseases. The company’s lead platform, NurOwn, uses a patient’s own bone marrow-derived mesenchymal stem cells, which are processed to secrete neurotrophic factors and then administered back to the patient. BrainStorm has investigated NurOwn as a potential treatment for conditions involving neuronal damage and degeneration.

The company’s clinical development work has focused primarily on amyotrophic lateral sclerosis (ALS), as well as progressive multiple sclerosis and other neurodegenerative disorders. BrainStorm has conducted clinical studies in the United States and has evaluated NurOwn’s potential to support nerve-cell survival, reduce inflammation and promote repair-related biological activity. The company has also pursued regulatory review of NurOwn in the United States, although the therapy has not received broad marketing approval.

BrainStorm Cell Therapeutics is headquartered in Israel and operates as a research-focused biotechnology company serving the international clinical-development market. Chaim Lebovits has served as the company’s chief executive officer, and the company’s programs have been developed through collaborations with academic, clinical and research institutions.